SCHEMBL6522892

SCHEMBL6522892

O=C(Nc1ccccc1)c1cnc2nc(Nc3ccccc3)c3ccccc3c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.50
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ABCG2 Q9UNQ0 3/20 0.46
P4HTM Q9NXG6 1/20 0.46
ADORA3 P0DMS8 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
AURKA O14965 3/20 0.45
EGFR P00533 2/20 0.45
AURKB Q96GD4 2/20 0.45
INCENP Q9NQS7 1/20 0.45
POLB P06746 1/20 0.44
RPS6KB1 P23443 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6521635 0.84 NPC1 (0.52) ALDH1A1NPC1RAB9AKDM4EP4HTM
SCHEMBL6525797 0.76 ABCG2 (0.50) CSNK2A1ALDH1A1KDM4EABCG2MEN1
SCHEMBL6521521 0.72 BRD4 (0.57) ALDH1A1NPC1RAB9AKDM4EP4HTM
SCHEMBL30958690 0.70 KDR (0.73) ALDH1A1NPC1RAB9AKDM4E
SCHEMBL327090 0.70 KDR (0.73) ALDH1A1NPC1RAB9AKDM4E
SCHEMBL9076442 0.68 HCAR3 (0.73) ALDH1A1NPC1RAB9AKDM4EP4HTM
SCHEMBL23360530 0.68 KMT2A (0.52) ALDH1A1NPC1RAB9AKDM4EP4HTM
SCHEMBL19382455 0.67 KDM4E (0.62) ALDH1A1NPC1RAB9AKDM4EP4HTM
SCHEMBL4972017 0.67 CSNK2A1 (1.00) CSNK2A1CSNK2A2CSNK2B
SCHEMBL26784631 0.67 AURKB (0.68) NPC1RAB9AABCG2ADORA3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 CSNK2A1 121/4885ALDH1A1 4501/4885NPC1 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.